Group 1 - The core viewpoint of the article highlights the upward trend in brain-computer interface (BCI) concept stocks, driven by supportive government policies and technological advancements [1] - As of the report, notable stock performances include Brainhole Aurora-B (06681) up 7.91% to HKD 7.78, Micron Brain Science (02172) up 6.2% to HKD 13.19, and Brainhole Technology (02203) up 3.56% to HKD 0.233 [1] - The Ministry of Industry and Information Technology, along with eight other departments, issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'" on January 7, focusing on accelerating the upgrade of smart terminals and emphasizing the industrialization and commercialization of new terminals like AR/VR devices and BCIs [1] Group 2 - Financial analysts believe that the BCI industry is entering a critical phase of scaling applications, supported by strong policy backing, the implementation of medical insurance payments, and continuous technological breakthroughs [1] - Guosen Securities indicates that the BCI sector is at a pivotal point of transitioning from technological breakthroughs to commercialization, driven by a combination of policies, technology, and application scenarios [1] - The industry is expected to benefit from the "14th Five-Year Plan" focus, medical insurance coding, and the establishment of medical device standards, alongside anticipated mass production of Neuralik and breakthroughs in domestic clinical applications, leading to explosive growth in the global market [1]

Core Viewpoint - The company, Brainstorm Aurora-B (06681), has signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Business Developments - The company’s stock price increased by 8.46%, currently trading at 7.82 HKD with a transaction volume of 149 million HKD [1][4]. - The collaboration with Peking University Sixth Hospital and Shandong Mental Health Center aims to enhance the development of mental health digital therapy products [1][4]. - The company has also received approval to establish the "Precision Intelligent Diagnosis and Treatment Innovation and Transformation Key Laboratory for Mental Disorders" in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering [1][4]. Group 2: Strategic Partnerships - The company has formed a close commercial partnership with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disorders, to promote the clinical application of mental health digital therapy products [1][4]. - The recent partnerships expand the company's network within core mental health specialty hospitals across the country, creating a comprehensive commercial implementation network from national flagship centers to regional hubs and key specialty hospitals [1][4].

Core Viewpoint - The company, Brainstorm Cell Therapeutics-B (06681), has seen its stock price increase by over 8%, currently trading at 7.75 HKD with a transaction volume of 58.17 million HKD, following the announcement of significant business collaborations aimed at advancing digital therapies for mental health [1] Group 1: Business Collaborations - The company has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to jointly promote the research and commercialization of digital therapy products for mental health [1] - The collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University has led to the establishment of a key laboratory for precision intelligent diagnosis and treatment of mental disorders in Beijing [1] Group 2: Clinical Applications and Network Expansion - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disease medicine, to promote the clinical application of digital therapy products for mental health [1] - The recent partnerships further expand the company's presence in core mental health specialty hospitals across the country, creating a comprehensive commercial network from national flagship centers to regional hubs and key specialty hospitals [1]

Core Viewpoint - The company, Brainstorm Aurora-B (06681), has seen its stock price increase by over 8%, currently trading at 7.75 HKD with a transaction volume of 58.17 million HKD, following the announcement of significant business collaborations aimed at advancing digital therapies for mental health [1] Group 1: Business Collaborations - The company has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to jointly promote the research and commercialization of digital therapy products for mental health [1] - The collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University has led to the establishment of a key laboratory for precision intelligent diagnosis and treatment of mental disorders in Beijing [1] Group 2: Clinical Applications and Network Expansion - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disorders, to promote the clinical application of digital therapy products for mental health [1] - The recent partnerships further expand the company's presence in core mental health specialty hospitals across the country, creating a comprehensive commercial network from national flagship centers to regional hubs and key specialty hospitals [1]

Group 1 - The core point of the article highlights that Brainstorm Aurora-B (06681) has deposited shares worth HKD 1.959 billion into Guotai Junan (Hong Kong), representing 20.77% of the total shareholding [2] Group 2 - Brainstorm Aurora has recently signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [3] - The company, in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has successfully applied for the establishment of the "Beijing Key Laboratory for Precision Intelligent Diagnosis and Treatment of Mental Disorders" [3]

Group 1 - The core viewpoint of the article highlights that Brainstorm Aurora-B (06681) has deposited shares worth HKD 1.959 billion into Guotai Junan (Hong Kong), representing 20.77% of the total shareholding [1] - The company has recently signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1] - Additionally, the joint application for the "Precision Intelligent Diagnosis and Treatment Innovation and Transformation Key Laboratory for Mental Disorders" with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering has been officially approved for establishment [1]

Major Events - Brain动极光-B (06681) signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center [1] - Cohere New Energy (00182) successfully completed a secondary listing on the Singapore Stock Exchange [1] - Bole康视云-B (02592) submitted a clinical trial application for the new drug CBT-009 to the Drug Evaluation Center [1] - Yingtong Holdings (06883) established a partnership with the Italian high-end fragrance brand CULTI to strengthen its high-end fragrance distribution network in China [1] - Weimeng Group (02013) initiated a business cooperation with Taobao Flash Purchase [1] - Dali普控股 (01921) officially became a qualified supplier for Saudi Aramco [1] - Yiming Anke-B (01541) regained global rights for IMM2510 and IMM27M [1] - Yuexiu Property (00123) subsidiary Shanghai Yuheng won a land parcel in Shanghai's Pudong New District [1] Operating Performance - Jinxin Reproductive (01951) reported a further narrowing of the overall decline in IVF egg retrieval cycles to -1.4% for 2025 [1] - Poly Real Estate Group (00119) achieved a cumulative contract sales amount of approximately 50.2 billion yuan for 2025, a year-on-year decrease of 7.38% [1] - Yadea Holdings (01585) issued a profit warning, expecting annual net profit to be no less than 2.9 billion yuan [1] - Jindi Commercial Real Estate (00535) reported a cumulative contract sales total of approximately 10.696 billion yuan for 2025, a year-on-year decrease of 47.33% [1] - Greentown Management Holdings (09979) estimated the construction fee for newly developed projects in 2025 to be 9.35 billion yuan, a year-on-year increase of approximately 0.4% [1] - Sunac China (01918) achieved a cumulative contract sales amount of approximately 36.84 billion yuan for 2025, a year-on-year decrease of 21.85% [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | 0 | | | USD | | 0 | | 本月底結存 | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | 本月底法定/註冊股本總 ...

Core Viewpoint - The company has signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Collaboration Details - The collaboration with Peking University Sixth Hospital includes the development of digital therapies and clinical application research, focusing on ADHD cognitive digital therapy effectiveness and a precision intelligent diagnosis system for depression [2]. - The research scope encompasses developing digital therapy products for emotional and behavioral issues across the entire lifecycle, including clinical validation of cognitive digital therapies aimed at improving learning abilities in children with ADHD [2]. - The partnership with Shandong Provincial Mental Health Center involves developing cognitive screening and intervention systems for mental disorders, as well as methods for capacity training guided by virtual humans [3]. Group 2: Laboratory Establishment - The "Precision Intelligent Diagnosis and Innovation Transformation Key Laboratory for Mental Diseases" has been officially approved, with the company as a core co-construction unit alongside Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering [3]. - The laboratory will focus on innovation and transformation driven by clinical needs in mental health, integrating clinical medicine, basic research, technology development, and hardware innovation [3]. Group 3: Strategic Positioning - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health facility, to promote the clinical application of digital mental health therapies [4]. - The recent collaborations expand the company's network across key mental health hospitals in China, creating a comprehensive commercial landing network from national flagship centers to regional hubs and specialized hospitals [4]. - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the digital mental health therapy field, accelerating product development and commercialization [4].

Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Collaboration Details - The collaboration with Beijing University Sixth Hospital includes the development of digital therapies and clinical application research, focusing on attention deficit hyperactivity disorder (ADHD) cognitive digital therapy and a precision intelligent diagnosis system for depression [2]. - The research scope encompasses the development of digital therapy products for emotional and behavioral issues across the entire lifecycle, including clinical validation of cognitive digital therapies aimed at improving learning abilities in children with ADHD [2]. - The partnership with Shandong Provincial Mental Health Center involves the development of cognitive screening and intervention systems for mental disorders, as well as methods for capacity training guided by virtual humans [3]. Group 2: Laboratory Establishment - The "Precision Intelligent Diagnosis and Innovation Transformation Key Laboratory for Mental Diseases" has been officially approved, with the company as a core co-construction unit alongside Beijing University Sixth Hospital and the National Engineering Research Center for Software Engineering [3]. - The laboratory will focus on innovation and transformation driven by clinical needs in mental health, integrating clinical medicine, basic research, technology development, and hardware innovation [3]. Group 3: Strategic Positioning - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health facility, to promote the clinical application of digital mental health therapies [4]. - The recent collaborations further expand the company's network within core mental health specialty hospitals across the country, creating a comprehensive commercial landing network from national flagship centers to regional hubs and key specialty hospitals [4]. - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's first-mover advantage in the digital mental health therapy sector, accelerating product development and commercialization processes [4].